---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-174947"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:36:07.960696+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO amends AbbVie deal; restructures $200M milestones, starts DR pivotal; Q2 net loss $70.9M

## Summary
- Amendment to AbbVie collaboration: $100M milestone upon first pt dosed in Phase IIb/III DR trial, additional $100M upon first pt in Phase III.
- REGENXBIO to pay costs for Phase IIb of that trial; AbbVie to fund new Phase III wAMD study (ACHIEVE).
- Q2 net loss $70.9M ($1.38/share) vs $53.0M loss year ago; revenue $21.4M, down from $22.3M.
- Cash $363.6M at June 30, 2025; expects to fund operations into early 2027.
- RGX-202 Duchenne pivotal enrollment accelerated, to complete Oct 2025; topline data 1H 2026.

## SEC filing metadata
- accession: 0001193125-25-174947
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000119312525174947/0001193125-25-174947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000119312525174947/rgnx-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-174947
- JSON: https://secwatch.observer/filing/0001193125-25-174947.json
- Plain text: https://secwatch.observer/filing/0001193125-25-174947.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.